The Impact of 27-Hydroxycholesterol, a Macrophage-Produced Estrogen Receptor and Liver X Receptor Agonist, on Breast Cancer Pathophysiology

2011 ◽  
Author(s):  
Donald P. McDonnell
Keyword(s):  
Breast Cancer ◽  
Estrogen Receptor ◽  
Receptor Agonist ◽  
Liver X Receptor ◽  
The Impact ◽  
Liver X Receptor Agonist

scholarly journals Stimulation of Cholesterol Excretion by the Liver X Receptor Agonist Requires ATP-binding Cassette Transporters G5 and G8

2003 ◽  
Vol 278 (18) ◽  
pp. 15565-15570 ◽  
Author(s):  
Liqing Yu ◽  
Jennifer York ◽  
Klaus von Bergmann ◽  
Dieter Lutjohann ◽  
Jonathan C. Cohen ◽  
...  
Keyword(s):  
Receptor Agonist ◽  
Liver X Receptor ◽  
Atp Binding ◽  
Atp Binding Cassette Transporters ◽  
Cholesterol Excretion ◽  
Liver X Receptor Agonist ◽  
Stimulation Of ◽  
Atp Binding Cassette

scholarly journals The liver X receptor agonist LXR 623 restricts flavivirus replication

2021 ◽  
pp. 1-33
Author(s):  
Luwanika Mlera ◽  
Danielle K. Offerdahl ◽  
David W Dorward ◽  
Aaron Carmody ◽  
Abhilash I. Chiramel ◽  
...  
Keyword(s):  
Receptor Agonist ◽  
Liver X Receptor ◽  
Liver X Receptor Agonist

Plasma ESR1 Mutations and the Treatment of Estrogen Receptor–Positive Advanced Breast Cancer

2016 ◽  
Vol 34 (25) ◽  
pp. 2961-2968 ◽  
Author(s):  
Charlotte Fribbens ◽  
Ben O’Leary ◽  
Lucy Kilburn ◽  
Sarah Hrebien ◽  
Isaac Garcia-Murillas ◽  
...  
Keyword(s):  
Breast Cancer ◽  
Estrogen Receptor ◽  
Advanced Breast Cancer ◽  
Metastatic Breast ◽  
Advanced Breast ◽  
Phase Iii ◽  
Wild Type ◽  
Estrogen Receptor Positive ◽  
Esr1 Mutations ◽  
The Impact

Purpose ESR1 mutations are selected by prior aromatase inhibitor (AI) therapy in advanced breast cancer. We assessed the impact of ESR1 mutations on sensitivity to standard therapies in two phase III randomized trials that represent the development of the current standard therapy for estrogen receptor–positive advanced breast cancer. Materials and Methods In a prospective-retrospective analysis, we assessed ESR1 mutations in available archived baseline plasma from the SoFEA (Study of Faslodex Versus Exemestane With or Without Arimidex) trial, which compared exemestane with fulvestrant-containing regimens in patients with prior sensitivity to nonsteroidal AI and in baseline plasma from the PALOMA3 (Palbociclib Combined With Fulvestrant in Hormone Receptor–Positive HER2-Negative Metastatic Breast Cancer After Endocrine Failure) trial, which compared fulvestrant plus placebo with fulvestrant plus palbociclib in patients with progression after receiving prior endocrine therapy. ESR1 mutations were analyzed by multiplex digital polymerase chain reaction. Results In SoFEA, ESR1 mutations were found in 39.1% of patients (63 of 161), of whom 49.1% (27 of 55) were polyclonal, with rates of mutation detection unaffected by delays in processing of archival plasma. Patients with ESR1 mutations had improved progression-free survival (PFS) after taking fulvestrant (n = 45) compared with exemestane (n = 18; hazard ratio [HR], 0.52; 95% CI, 0.30 to 0.92; P = .02), whereas patients with wild-type ESR1 had similar PFS after receiving either treatment (HR, 1.07; 95% CI, 0.68 to 1.67; P = .77). In PALOMA3, ESR1 mutations were found in the plasma of 25.3% of patients (91 of 360), of whom 28.6% (26 of 91) were polyclonal, with mutations associated with acquired resistance to prior AI. Fulvestrant plus palbociclib improved PFS compared with fulvestrant plus placebo in both ESR1 mutant (HR, 0.43; 95% CI, 0.25 to 0.74; P = .002) and ESR1 wild-type patients (HR, 0.49; 95% CI, 0.35 to 0.70; P < .001). Conclusion ESR1 mutation analysis in plasma after progression after prior AI therapy may help direct choice of further endocrine-based therapy. Additional confirmatory studies are required.

Liver X receptor agonist T0901317 reduces atherosclerotic lesions in apoE-/- mice by up-regulating NPC1 expression

2008 ◽  
Vol 51 (5) ◽  
pp. 418-429 ◽  
Author(s):  
Xiang Ou ◽  
XiaoYan Dai ◽  
ZhiFeng Long ◽  
YaLing Tang ◽  
DongLi Cao ◽  
...  
Keyword(s):  
Receptor Agonist ◽  
Liver X Receptor ◽  
Atherosclerotic Lesions ◽  
Liver X Receptor Agonist
Sign in / Sign up

Export Citation Format

Share Document